|
|
||||||||
-MSH
J. M. Lipton was previously in the Department of Physiology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235-9040 and is now Chief Scientific Officer of ZENGEN, Inc., Woodland, California; A. Catania is in the Neuroimmunomodulation Laboratory, IRCCS Ospedale Maggiore, Milan, Italy 20122; and T. Ichiyama is at the Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
Inflammation in peripheral tissues should benefit from a novel focus on descending neuroimmunomodulatory anti-inflammatory influences stemming from CNS receptors for the peptide
-MSH. Because activation of glial and peripheral cell receptors modulates inflammatory activity,
-MSH peptides may aid treatment of a variety of CNS and peripheral inflammatory disorders. Activation of melanocortin receptors should thus promote control of inflammatory diseases.
This article has been cited by other articles:
![]() |
L. Kang, K. W. McIntyre, K. M. Gillooly, Y. Yang, J. Haycock, S. Roberts, A. Khanna, T. F. Herpin, G. Yu, X. Wu, et al. A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice J. Leukoc. Biol., October 1, 2006; 80(4): 897 - 904. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Lam, S. J. Getting, and M. Perretti In Vitro and In Vivo Induction of Heme Oxygenase 1 in Mouse Macrophages following Melanocortin Receptor Activation J. Immunol., February 15, 2005; 174(4): 2297 - 2304. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Catania, S. Gatti, G. Colombo, and J. M. Lipton Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation Pharmacol. Rev., March 1, 2004; 56(1): 1 - 29. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |